Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

This randomized, open-label, active-controlled, dose-finding phase IIb study evaluated the efficacy and safety of trabedersen (AP 12009) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent/refractory high-grade glioma. One hundre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N.K., Mahapatra, A.K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., Poverennova, I., Zaaroor, M., Jachimczak, P., Ludwig, S., Schmaus, S., Heinrichs, H., Schlingensiepen, K.-H.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018908/
https://www.ncbi.nlm.nih.gov/pubmed/20980335
http://dx.doi.org/10.1093/neuonc/noq142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018908/
https://www.ncbi.nlm.nih.gov/pubmed/20980335
http://dx.doi.org/10.1093/neuonc/noq142

Ejemplares similares